The Board of Trustees of the Leland Stanford Junior University;Chan Zuckerberg Biohub, Inc.
发明人:
CLARKE, Michael F.,HSIEH, Robert W.
申请号：
AU2018333072
公开号：
AU2018333072A1
申请日:
2018.09.18
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The invention is directed to methods of treating TNBC in a patient by administering to the patient an agent that inhibits the expression or activity of cyclin-dependent kinase 19 (CDK19). In some embodiments, the agent may be a small molecule inhibitor, a polynucleotide (e.g., shRNA. siRNA), or a protein (e.g., an antibody). In some embodiments, the agent does not inhibit the activity or expression of CDK8.
